Physician profile
Nathan D Granger
NPI 1144288002
$1,720.77
in general payments reported to CMS, 2019-2025
26 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $110 · 2021: $454 · 2022: $289 · 2023: $72.16 · 2024: $120 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $371.35 | 2019-2023 | |
| Pfizer INC. | $230.21 | 2019-2022 | |
| Novo Nordisk INC | $229.01 | 2019-2022 | |
| Abbott Laboratories | $100.03 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $83.06 | 2019-2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $79.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Nevro Corp. | $73.58 | 2022-2024 | Senza |
| Lilly USA, LLC | $70.88 | 2021-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.53 | 2019-2021 | |
| Shire North American Group INC | $56.56 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $55.03 | 2020-2024 | Breztri |
| Vertex Pharmaceuticals Incorporated | $37.79 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.38 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.17 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $22.83 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $21.74 | 2025 | Paradise Ultrasound Renal Denervation System |
| Amarin Pharma, INC. | $21.65 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.56 | 2019 | |
| Astellas Pharma US INC | $18.10 | 2019 | |
| Ardelyx, INC. | $17.36 | 2025 | Ibsrela |
| Inspire Medical Systems, INC. | $14.92 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $14.17 | 2022 | |
| Corcept Therapeutics | $14.08 | 2024 | Korlym |
| Boston Scientific Corporation | $13.84 | 2024 | Watchman Flx |
| Gilead Sciences, INC. | $13.76 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $12.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Granger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.